Rachel Passow

University of Minnesota — United States

Medicine · Health Sciences

3h-index22citations61works0.42yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(46), PARP inhibition in cancer therapy(32), Science, Research, and Medicine(19), FOXO transcription factor regulation(11), Cancer Genomics and Diagnostics(10)

Publications61 total

Supplementary Figure 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

2025Open Access

Supplementary Table 3 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

2025Open Access

Supplementary Figure 3 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

2025Open Access

Supplementary Table 1 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

2025Open Access

Supplementary Table 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

2025Open Access

Supplementary Figure 1 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

2025Open Access

HLA class I expression shapes the tumor immune microenvironment and influences prognosis in prostate cancer

1 cited

Prostate Cancer and Prostatic Diseases·2025· 1 citedOpen Access

Supplementary Figure 1-10 from Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes

2025Open Access

Figure 6 from Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes

2025Open Access

Figure 5 from Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes

2025Open Access

Table 1 from Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes

2025Open Access

Supplementary Table 1-11 from Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes

2025Open Access

Figure 2 from Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes

2025Open Access

Data from Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes

2025Open Access

Figure 4 from Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes

2025Open Access

Figure 3 from Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes

2025Open Access

Figure 1 from Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes

2025Open Access

Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes

9 cited

Clinical Cancer Research·2025· 9 citedOpen Access

Supplementary Figure 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

2024Open Access

Supplementary Table 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

2024Open Access

page 1 of 4Next →

Frequent Co-authors

Justin H. Hwang(50), Andrew Elliott(49), Eamon Toye(49), Emmanuel S. Antonarakis(49), Rana R. McKay(48), Elisabeth I. Heath(47), Chadi Nabhan(47), Hannah E. Bergom(39), Charles J. Ryan(39), Julie McGrath(38), Abderrahman Day(38), Allison Makovec(38), Benedito A. Carneiro(38), W. Michael Korn(38), Xiaolei Shi(37), Taylor E. Arnoff(37), Joanne Xiu(37), Phillip Walker(37), Shihab Ahmed(37), Sydney Tape(37)